GSK 3206641A
Alternative Names: FLU-Q-PAN H7N9; GSK Biologicals' influenza vaccine GSK3206641A; GSK-3206641ALatest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator GlaxoSmithKline Biologicals
- Class Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N9 subtype
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Influenza-A virus H7N9 subtype(In the elderly, Prevention, In adults) in USA (IM, Injection)
- 12 Sep 2022 GlaxoSmithKline completes phase I trial in Influenza A virus H7N9 subtype (In adults, In the elderly, Prevention) in USA (IM) (NCT04789577)
- 16 Mar 2021 Phase-I clinical trials in Influenza A virus H7N9 subtype (In adults, In the elderly, Prevention) in USA (IM) (NCT04789577)